Farallon Capital Management LLC Nuvation Bio Inc. Transaction History

Farallon Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.6 - $2.48 $1.04 Million - $1.62 Million	-652,600 Reduced 30.82%	1,465,000 $2.43 Million
Q4 2022 Feb 14, 2023	SELL	$1.68 - $2.5 $1.31 Million - $1.96 Million	-782,400 Reduced 26.98%	2,117,600 $4.07 Million
Q1 2022 May 16, 2022	BUY	$4.6 - $8.83 $6.76 Million - $13 Million	1,470,000 Added 102.8%	2,900,000 $15.3 Million
Q4 2021 Feb 14, 2022	SELL	$7.75 - $10.05 $6.05 Million - $7.84 Million	-780,000 Reduced 35.29%	1,430,000 $12.2 Million
Q3 2021 Nov 15, 2021	SELL	$7.78 - $10.0 $2.25 Million - $2.89 Million	-288,600 Reduced 11.55%	2,210,000 $22 Million
Q2 2021 Aug 13, 2021	SELL	$9.22 - $14.48 $12,908 - $20,272	-1,400 Reduced 0.06%	2,498,600 $23.3 Million
Q1 2021 May 17, 2021	BUY	$9.0 - $14.57 $22.5 Million - $36.4 Million	2,500,000 New	2,500,000 $26.1 Million

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Farallon Capital Management LLC with notifications on news.